Altimmune, Inc. (ALT) Q2 FY26 Earnings Call

Strong AUD Phase 2 efficacy advances a potential liver franchise, but AUD Phase 3 timing and funding remain unresolved [3][9].

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-12
Length61 minutes
EPS$-0.12
EPS consensus$-0.15
Revenue$4.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All ALT earnings ยท Back to ALT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.